Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Subscribe To Our Newsletter & Stay Updated
